Abstract
Most proteins undergo post-translational modification (PTM), which is known to play roles in normal physiological processes and the progression of many diseases. In this review, we summarized and discussed the mass spectrometry (MS)-based studies of various PTMs of nuclear co-repressor, receptor interacting protein 140 (RIP140), as well as the significance of these PTMs in modulating the biological activities of RIP140, specifically in adipocytes. Comprehensive analyses of RIP140 by MS identified specific sites of PTMs on RIP140, including that of phosphorylation, acetylation, pyridoxylation, and protein arginine methylation. Studies of these PTMs revealed their combinatorial effects on the activities of RIP140 with respect to the regulation of hormone target genes and fat accumulation in adipocytes. These proteomic studies have presented evidence for the biological significance of specific PTMs of RIP140, and uncovered nutritional and physiological factors that trigger these PTMs in adipocytes.. This could provide insights into potential, new therapeutic targets for diseases concerning adipocytes such as metabolic disorders.
Keywords: RIP140, protein posttranslational modification, proteomics, mass spectrometry, metabolic diseases, drug discovery
Current Medicinal Chemistry
Title: Post-Translational Modifications of Nuclear Co-repressor RIP140: A Therapeutic Target for Metabolic Diseases
Volume: 15 Issue: 4
Author(s): Li-Na Wei, M. D. Mostaqul Huq and Pawan Gupta
Affiliation:
Keywords: RIP140, protein posttranslational modification, proteomics, mass spectrometry, metabolic diseases, drug discovery
Abstract: Most proteins undergo post-translational modification (PTM), which is known to play roles in normal physiological processes and the progression of many diseases. In this review, we summarized and discussed the mass spectrometry (MS)-based studies of various PTMs of nuclear co-repressor, receptor interacting protein 140 (RIP140), as well as the significance of these PTMs in modulating the biological activities of RIP140, specifically in adipocytes. Comprehensive analyses of RIP140 by MS identified specific sites of PTMs on RIP140, including that of phosphorylation, acetylation, pyridoxylation, and protein arginine methylation. Studies of these PTMs revealed their combinatorial effects on the activities of RIP140 with respect to the regulation of hormone target genes and fat accumulation in adipocytes. These proteomic studies have presented evidence for the biological significance of specific PTMs of RIP140, and uncovered nutritional and physiological factors that trigger these PTMs in adipocytes.. This could provide insights into potential, new therapeutic targets for diseases concerning adipocytes such as metabolic disorders.
Export Options
About this article
Cite this article as:
Wei Li-Na, Mostaqul Huq D. M. and Gupta Pawan, Post-Translational Modifications of Nuclear Co-repressor RIP140: A Therapeutic Target for Metabolic Diseases, Current Medicinal Chemistry 2008; 15 (4) . https://dx.doi.org/10.2174/092986708783497382
DOI https://dx.doi.org/10.2174/092986708783497382 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Serous BMP8A has Clinical Significance in the Ultrasonic Diagnosis of Thyroid Cancer and Promotes Thyroid Cancer Cell Progression
Endocrine, Metabolic & Immune Disorders - Drug Targets MicroRNAs in Cancer Therapy: From Bench to Bedside
Current Cancer Therapy Reviews Genetic Variants in Genes Involved in Mechanisms of Chemoresistance to Anticancer Drugs
Current Cancer Drug Targets The Application of Rational Design on Phospholipase A2 Inhibitors
Current Medicinal Chemistry Editorial (Thematic Issue: Thyroid Hormones. From Molecular Signaling to Human Disease: An Update)
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Cardiovascular Tests: Use & Limits of Biochemical Markers - Therapeutic Measurements of ADMA Involved in Cardiovascular Disorders
Current Pharmaceutical Design The Anti-Tumor Activity of Afatinib in Pancreatic Ductal Adenocarcinoma Cells
Anti-Cancer Agents in Medicinal Chemistry Retinoids and Retinoid Receptors in the Control of Energy Balance: Novel Pharmacological Strategies in Obesity and Diabetes
Current Medicinal Chemistry Tachykinins and their Receptors in Human Malignancies
Current Drug Targets What are the Cancer Risks in BRCA Carriers Apart from Those Regarding the Breast and the Ovary?
Current Women`s Health Reviews Targeting the Tumor Stroma in Cancer Therapy
Current Pharmaceutical Biotechnology Protein Misfolding in Conformational Disorders: Rescue of Folding Defects and Chemical Chaperoning
Mini-Reviews in Medicinal Chemistry Transcriptional Regulation of mPGES1 in Cancer: An Alternative Approach to Drug Discovery?
Current Drug Targets NF-κB Inhibitors in Head and Neck Cancer
Letters in Drug Design & Discovery What is the Optimal Treatment for Anemia in Inflammatory Bowel Disease?
Current Drug Delivery Metal Release from and Sequestration by Metallothioneins Monitored by Electrochemistry and SPR
Current Pharmaceutical Biotechnology Biosynthesis of Peptide Hormones Derived from Precursor Sequences
Current Medicinal Chemistry Structure-Activity Relationships of Flavonoids
Current Organic Chemistry In vitro Antioxidant, α-amylase and Horseradish Peroxidase Inhibitory Potential of Phenolics Extracts from Chamomilla pubescens, Pulicaria crispa and Rhanterium adpressum Growing in Algeria
Current Enzyme Inhibition Editorial [Hot topic: Role of Apoptosis in Chemotherapy (Guest Editors: George G. Chen and Paul B.S. Lai)]
Current Drug Targets